Anti-inflammatory and immunoregulatory effects of pinolenic acid in rheumatoid arthritis
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology..
OBJECTIVES: In pre-clinical studies, pinolenic acid (PNLA), an omega-6-polyunsaturated fatty acid from pine nuts, has shown anti-inflammatory effects. We aimed to investigate the effect of PNLA in human cell lines and peripheral blood mononuclear cells (PBMCs) from RA patients and healthy controls (HCs).
METHODS: A modified Boyden chamber was used to assess chemokine-induced migration of THP-1 monocytes. Macropinocytosis was assessed using Lucifer yellow and oxidized low-density lipoprotein (oxLDL) uptake using DiI-labelled oxLDL in THP-1 macrophages and human monocyte-derived macrophages (HMDMs). IL-6, TNF-α and prostaglandin E2 (PGE2) release by lipopolysaccharide (LPS)-stimulated PBMCs from RA patients and HCs was measured by ELISA. The transcriptomic profile of PNLA-treated, LPS-activated PBMCs was investigated by RNA-sequencing.
RESULTS: PNLA reduced THP-1 cell migration by 55% (P < 0.001). Macropinocytosis and DiI-oxLDL uptake were reduced by 50% (P < 0.001) and 40% (P < 0.01), respectively, in THP-1 macrophages and 40% (P < 0.01) and 25% (P < 0.05), respectively, in HMDMs. PNLA reduced IL-6 and TNF-α release from LPS-stimulated PBMCs from RA patients by 60% (P < 0.001) and from HCs by 50% and 35%, respectively (P < 0.01). PNLA also reduced PGE2 levels in such PBMCs from RA patients and HCs (P < 0.0001). Differentially expressed genes whose expression was upregulated included pyruvate dehydrogenase kinase-4, plasminogen activator inhibitor-1, fructose bisphosphatase1 and N-Myc downstream-regulated gene-2, which have potential roles in regulating immune and metabolic pathways. Pathway analysis predicted upstream activation of the nuclear receptors peroxisome proliferator-activated receptors involved in anti-inflammatory processes, and inhibition of nuclear factor-κB and signal transducer and activator of transcription 1.
CONCLUSIONS: PNLA has immune-metabolic effects on monocytes and PBMCs that are pathogenic in RA and atherosclerosis. Dietary PNLA supplementation may be beneficial in RA.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
---|---|
Enthalten in: |
Rheumatology (Oxford, England) - 61(2022), 3 vom: 02. März, Seite 992-1004 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Takala, Rabaa [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.03.2022 Date Revised 14.03.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/rheumatology/keab467 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM326289860 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM326289860 | ||
003 | DE-627 | ||
005 | 20231225194255.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/rheumatology/keab467 |2 doi | |
028 | 5 | 2 | |a pubmed24n1087.xml |
035 | |a (DE-627)NLM326289860 | ||
035 | |a (NLM)34080609 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Takala, Rabaa |e verfasserin |4 aut | |
245 | 1 | 0 | |a Anti-inflammatory and immunoregulatory effects of pinolenic acid in rheumatoid arthritis |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.03.2022 | ||
500 | |a Date Revised 14.03.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. | ||
520 | |a OBJECTIVES: In pre-clinical studies, pinolenic acid (PNLA), an omega-6-polyunsaturated fatty acid from pine nuts, has shown anti-inflammatory effects. We aimed to investigate the effect of PNLA in human cell lines and peripheral blood mononuclear cells (PBMCs) from RA patients and healthy controls (HCs) | ||
520 | |a METHODS: A modified Boyden chamber was used to assess chemokine-induced migration of THP-1 monocytes. Macropinocytosis was assessed using Lucifer yellow and oxidized low-density lipoprotein (oxLDL) uptake using DiI-labelled oxLDL in THP-1 macrophages and human monocyte-derived macrophages (HMDMs). IL-6, TNF-α and prostaglandin E2 (PGE2) release by lipopolysaccharide (LPS)-stimulated PBMCs from RA patients and HCs was measured by ELISA. The transcriptomic profile of PNLA-treated, LPS-activated PBMCs was investigated by RNA-sequencing | ||
520 | |a RESULTS: PNLA reduced THP-1 cell migration by 55% (P < 0.001). Macropinocytosis and DiI-oxLDL uptake were reduced by 50% (P < 0.001) and 40% (P < 0.01), respectively, in THP-1 macrophages and 40% (P < 0.01) and 25% (P < 0.05), respectively, in HMDMs. PNLA reduced IL-6 and TNF-α release from LPS-stimulated PBMCs from RA patients by 60% (P < 0.001) and from HCs by 50% and 35%, respectively (P < 0.01). PNLA also reduced PGE2 levels in such PBMCs from RA patients and HCs (P < 0.0001). Differentially expressed genes whose expression was upregulated included pyruvate dehydrogenase kinase-4, plasminogen activator inhibitor-1, fructose bisphosphatase1 and N-Myc downstream-regulated gene-2, which have potential roles in regulating immune and metabolic pathways. Pathway analysis predicted upstream activation of the nuclear receptors peroxisome proliferator-activated receptors involved in anti-inflammatory processes, and inhibition of nuclear factor-κB and signal transducer and activator of transcription 1 | ||
520 | |a CONCLUSIONS: PNLA has immune-metabolic effects on monocytes and PBMCs that are pathogenic in RA and atherosclerosis. Dietary PNLA supplementation may be beneficial in RA | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a PBMCs | |
650 | 4 | |a inflammatory cytokines | |
650 | 4 | |a lipid uptake | |
650 | 4 | |a macropinocytosis | |
650 | 4 | |a pinolenic acid | |
650 | 4 | |a polyunsaturated fatty acids | |
650 | 4 | |a rheumatoid arthritis | |
650 | 7 | |a Interleukin-6 |2 NLM | |
650 | 7 | |a Linolenic Acids |2 NLM | |
650 | 7 | |a Lipoproteins, LDL |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
650 | 7 | |a 5,9,12-octadecatrienoic acid |2 NLM | |
650 | 7 | |a 13237-97-3 |2 NLM | |
650 | 7 | |a Dinoprostone |2 NLM | |
650 | 7 | |a K7Q1JQR04M |2 NLM | |
700 | 1 | |a Ramji, Dipak P |e verfasserin |4 aut | |
700 | 1 | |a Andrews, Robert |e verfasserin |4 aut | |
700 | 1 | |a Zhou, You |e verfasserin |4 aut | |
700 | 1 | |a Burston, James |e verfasserin |4 aut | |
700 | 1 | |a Choy, Ernest |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 61(2022), 3 vom: 02. März, Seite 992-1004 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
773 | 1 | 8 | |g volume:61 |g year:2022 |g number:3 |g day:02 |g month:03 |g pages:992-1004 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keab467 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 61 |j 2022 |e 3 |b 02 |c 03 |h 992-1004 |